Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 24M | 16M | 15M | 9M | 9M |
| Gross Profit | 11M | 8M | 6M | 3M | 2M |
| Operating Income | -1M | -4M | -8M | -13M | -10M |
| EBITDA | 1M | -3M | -6M | -11M | -7M |
| Net Income | -363K | -4M | -6M | -12M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$22.45
+0.40% today
1Y Change
+110.51%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Precipio, Inc. (PRPO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $22.45 and up 110.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +50.6%, EPS growth of +92.2%, a dividend yield of 0.0%. What stands out right now is revenue +50.6%, EPS +92.2%, free cash flow +66.2% with operating margin -5.0% and ROIC -6.6%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRPO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRPO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRPO Max Drawdown
-31.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRPO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.8M
-6.0% YoY
FY Net Income
-$8.6M
+29.9% YoY
Free Cash Flow
-$7.3M
+9.2% YoY
Revenue Growth
+50.6%
EPS Growth
+92.2%
Gross Margin
44.5%
Net Margin
-1.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 24M | 16M | 15M | 9M | 9M |
| Gross Profit | 11M | 8M | 6M | 3M | 2M |
| Operating Income | -1M | -4M | -8M | -13M | -10M |
| EBITDA | 1M | -3M | -6M | -11M | -7M |
| Net Income | -363K | -4M | -6M | -12M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 1M | 2M | 3M | 12M |
| Total Assets | 21M | 17M | 18M | 22M | 30M |
| Total Liabilities | 7M | 5M | 4M | 5M | 6M |
| Shareholder Equity | 15M | 12M | 14M | 16M | 25M |
| Total Debt | 4M | 1M | 1M | 1M | 1M |
| Net Debt | -2M | -136K | -386K | -2M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+14.8% YoY
Capital Expenditures
682K
-146.2% YoY
Free Cash Flow
7M
+9.2% YoY
Key ratios
Gross Margin
44.5%
Operating Margin
-5.0%
Net Margin
-1.5%
ROE
-2.8%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.